ライフサイエンスコーパス: glucagon-like peptide 1

1 he satiety neuropeptides cholecystokinin and glucagon-like peptide 1.

2 mentation of fibroblast growth factor 21 and glucagon-like peptide 1.

3 changes in glucose, insulin, peptide YY, and glucagon-like peptide-1.

4 A 72-hour continuous infusion of either glucagon-like peptide-1 (1.5 pmol/kg/min) or normal sali

5 e cleavage site, renders peptides, including glucagon-like peptide-1 (7-36) amide (GLP-1) and six oth

6 Glucagon-like peptide-1 (7-36) amide is a safe and effic

7 The incretin glucagon-like peptide-1 (7-36) amide is both insulinotro

8 Endogenous glucagon-like peptide-1 (7-36) is augmented by pharmacol

9 Sitagliptin increased plasma glucagon-like peptide-1 (7-36) levels and, at peak stres

10 enome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regul

11 This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to

12 by fusion of protease cleavable oligomers of glucagon-like peptide-1, a type-2 diabetes drug, and a t

13 together with the beneficial effects of the glucagon-like peptide-1 agonist exendin-4 in transgenic

14 odium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, and suggest how such d

15 e developed that were transfected to produce glucagon-like peptide-1, an incretin hormone with known

16 Weight-neutral treatment with a glucagon-like peptide-1 analog activates several cardiop

17 vestigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated

18 Here we examine the cardiac effects of the glucagon-like peptide-1 analog liraglutide in a model of

19 ation of beta-cells with an incretin hormone glucagon-like peptide-1 analog or with a fatty acid rece

20 Glucagon-like peptide-1 analogs are approved for type 2

21 These data support a role for glucagon-like peptide-1 analogs in limiting the cardiova

22 The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-l

23 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard

24 ontrolled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patien

25 trophy mice and further demonstrate that the glucagon-like peptide-1 analogue exendin-4, a well-toler

26 Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have

27 f target engagement for clinical trials with glucagon-like peptide-1 analogues in multiple system atr

28 Levels of glucagon-like peptide 1 and gastric inhibitory polypepti

29 with PS-CF and normal control subjects, and glucagon-like peptide 1 and gastric inhibitory polypepti

30 improves glucose tolerance while stimulating glucagon-like peptide 1 and insulin secretion.

31 ed with lower glucose and ghrelin and higher glucagon-like peptide 1 and peptide tyrosine-tyrosine re

32 Mean changes in serum glucagon-like peptide 1 and peptide YY were 106.6% +/- 2

33 ther dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and d

34 rolonging the half-life of incretins such as glucagon-like peptide-1 and gastric inhibitory peptide,

35 ysiological effects of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypepti

36 ieved, not all participants had increases in glucagon-like peptide-1 and gastrin concentrations that

37 ates Ca(2+) , cAMP, and insulin responses to glucagon-like peptide-1 and its metabolites following il

38 L-cells, better known for their secretion of glucagon-like peptide-1 and peptideYY.

39 ood glucose coefficient of variation for the glucagon-like peptide-1 and saline groups was 18.0% +/-

40 es of glucose, insulin, C-peptide, glucagon, glucagon-like peptides 1 and 2, gastric inhibitory pepti

41 y reports activation in response to insulin, glucagon-like peptide 1, and agents that raise cAMP leve

42 ve for either prolactin-releasing peptide or glucagon-like peptide 1, and attenuates the activation o

43 ut hormones, fibroblast growth factor 19 and glucagon-like peptide 1, and the BA transport systems, a

44 Glucagon-like peptide 1-based therapies, collectively de

45 Glucagon-like peptide-1-based (GLP-1-based) therapies im

46 The glucagon-like peptide-1 cohort (n = 9) and saline cohort

47 g, enhanced postprandial cholecystokinin and glucagon-like peptide 1 concentrations, and reduced ghre

48 Supplementation of FOS increased glucagon like peptide-1 content as well as Bifidobacteri

49 lunted the body weight-lowering effects of a glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

50 Administration of a recently developed glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

51 w focuses on two peptide drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type

52 fy 37 T2D patients who were actively using a Glucagon-like peptide 1 (GLP-1) agonist in addition to a

53 Glucagon-like peptide 1 (GLP-1) agonists have shown card

54 Glucagon-like peptide 1 (GLP-1) also has insulin-indepen

55 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is

56 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agon

57 ipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase

58 Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor ha

59 peptide possessing balanced coagonism at the glucagon-like peptide 1 (GLP-1) and glucagon receptors c

60 In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and i

61 Acute administration of glucagon-like peptide 1 (GLP-1) and its agonists slows g

62 herapeutic peptide hormone that combines the glucagon-like peptide 1 (GLP-1) and leptin via an IgG-Fc

63 sized that enteroendocrine L-cells producing glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may

64 ssed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) whe

65 Glucagon-like peptide 1 (GLP-1) and serotonin play criti

66 nsulin increased by 120% +/- 15% (P = 0.02), glucagon-like peptide 1 (GLP-1) by 60% +/- 20% (P < 0.01

67 ecretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by alpha cells and acts

68 Exocytosis of the hormone glucagon-like peptide 1 (GLP-1) by the intestinal L cell

69 Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective e

70 Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development

71 Glucagon-like peptide 1 (GLP-1) immunoreactivity of plas

72 Glucagon-like peptide 1 (GLP-1) is a hormone with essent

73 Glucagon-like peptide 1 (GLP-1) is a peptide hormone tha

74 The gut hormone called glucagon-like peptide 1 (GLP-1) is a strong moderator of

75 Glucagon-like peptide 1 (GLP-1) is secreted by intestina

76 The physiologic properties of glucagon-like peptide 1 (GLP-1) make it a potent candida

77 Moreover, ANP potentiated the effect of glucagon-like peptide 1 (GLP-1) on glucose-induced insul

78 The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeost

79 The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a k

80 armacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promot

81 Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1

82 Glucagon-like peptide 1 (GLP-1) receptor agonists induce

83 al models of type 2 diabetes have shown that glucagon-like peptide 1 (GLP-1) receptor agonists preven

84 e-18]fluoro-levodopa [(18)F-DOPA] PET-CT and glucagon-like peptide 1 (GLP-1) receptor imaging), and d

85 The glucagon-like peptide 1 (GLP-1) receptor is a class B G

86 Glucagon-like peptide 1 (GLP-1) reduces hyperglucagonemi

87 Glucagon-like peptide 1 (GLP-1) regulates glucose homeos

88 gon released from pancreatic alpha cells and glucagon-like peptide 1 (GLP-1) released from intestinal

89 The incretin hormone Glucagon-like peptide 1 (GLP-1) requires delivery by inj

90 Glucose is an important stimulus for glucagon-like peptide 1 (GLP-1) secretion, but the mecha

91 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) secretion, on glucose lo

92 in from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion.

93 enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve

94 This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardia

95 The contribution of elevated glucagon-like peptide 1 (GLP-1) to postprandial glucose

96 In contrast, glucagon-like peptide 1 (GLP-1) was approximately 64% hi

97 proof-of-principle, the clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with

98 Glucagon-like peptide 1 (GLP-1) was substantially increa

99 Upon a nutrient challenge, L cells produce glucagon-like peptide 1 (GLP-1), a powerful stimulant of

100 ty acids (FFAs), insulin, glucose, glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory

101 nificant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident

102 in plasma cholecystokinin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like pepti

103 poststimulation levels of glucose, insulin, glucagon-like peptide 1 (GLP-1), and glucose-dependent i

104 ) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved f

105 kinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine ty

106 wn at regular intervals for cholecystokinin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) an

107 been linked to the exaggerated secretion of glucagon-like peptide 1 (GLP-1), but causality has not b

108 elated to changes in blood peptide YY (PYY), glucagon-like peptide 1 (GLP-1), glucose, or insulin con

109 ing glucose, lipids (fasting only), insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

110 Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

111 RC1), general control nonrepressed 2 (GCN2), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), serot

112 Glucagon-like peptide 1 (GLP-1), produced in the intesti

113 Glucagon-like peptide 1 (GLP-1), secreted from intestina

114 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow

115 erhans is enhanced by the intestinal hormone glucagon-like peptide 1 (GLP-1), which is secreted from

116 Glucagon-like Peptide 1 (GLP-1)-expressing neurons in th

117 S) in the circulation and thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secreti

118 Here, we present evidence for glucagon-like peptide 1 (GLP-1)-mediated paraventricular

119 studies in subjects with diabetes receiving glucagon-like peptide 1 (GLP-1)-targeted therapies have

120 se of satiety-promoting gut hormones such as glucagon-like peptide 1 (GLP-1).

121 with increased secretion of the gut hormone glucagon-like peptide 1 (GLP-1).

122 increased postprandial levels of insulin and glucagon-like peptide 1 (GLP-1).

123 of either the accumulation or antagonism of glucagon-like peptide 1 (GLP-1).

124 se IV (DPP-IV) degrades the incretin hormone glucagon-like peptide 1 (GLP-1).

125 stimulates secretion of the incretin hormone glucagon-like peptide 1 (GLP-1).

126 elease of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1).

127 Potentiation of glucagon-like peptide-1 (GLP-1) action through selective

128 Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the

129 Glucagon-like peptide-1 (GLP-1) analogs are approved for

130 dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important n

131 ed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical dev

132 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 deve

133 al insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has

134 Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to s

135 Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic

136 Glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK

137 ate the anorectic effects of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 rece

138 creting glucagon, insulin, and the incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-depende

139 Incretin peptides (glucagon-like peptide-1 (GLP-1) and glucose-dependent in

140 esponses to glucose and to incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent in

141 , Tukey's post hoc, P < 0.05]; and increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) com

142 e of enteroendocrine L-cell derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in

143 elease of gastrointestinal peptides, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), fr

144 xendin-(9,39) is a competitive antagonist of glucagon-like peptide-1 (GLP-1) at its receptor.

145 circulating glucose, insulin, glucagon, and glucagon-like peptide-1 (GLP-1) concentrations and subje

146 d this increase is associated with increased glucagon-like peptide-1 (GLP-1) concentrations.

147 We have examined analogues of glucagon-like peptide-1 (GLP-1) containing beta-amino ac

148 red changes in cell health and intracellular glucagon-like peptide-1 (GLP-1) content.

149 Glucagon-like peptide-1 (GLP-1) controls glucose homeost

150 The peptide hormone glucagon-like peptide-1 (GLP-1) enhances glucose-induced

151 Multiple physiological properties of glucagon-like peptide-1 (GLP-1) ensure that it is a prom

152 In this study, we focused on the function of glucagon-like peptide-1 (GLP-1) in initial responses to

153 Pharmacological evidence suggests a role for glucagon-like peptide-1 (GLP-1) in modulating stress res

154 e acid synthesis and intestinal secretion of glucagon-like peptide-1 (GLP-1) in wild-type, Fxr(-/-),

155 Exogenous glucagon-like peptide-1 (GLP-1) inhibits eating in healt

156 Glucagon-like peptide-1 (GLP-1) is a hormone that stimul

157 Glucagon-like peptide-1 (GLP-1) is a natural agonist for

158 Glucagon-like peptide-1 (GLP-1) is an incretin that play

159 Glucagon-like peptide-1 (GLP-1) is both a peripherally e

160 ic polypeptide (GIP) is glucagonotropic, and glucagon-like peptide-1 (GLP-1) is glucagonostatic.

161 Glucagon-like peptide-1 (GLP-1) is produced in the ileum

162 Glucagon-like peptide-1 (GLP-1) is produced in the small

163 Glucagon-like peptide-1 (GLP-1) is released in response

164 The multiple physiological properties of glucagon-like peptide-1 (GLP-1) make it a promising drug

165 Since hindbrain glucagon-like peptide-1 (GLP-1) neurons and noradrenergi

166 Here we show that nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus t

167 impaired; this impairment is ameliorated by glucagon-like peptide-1 (GLP-1) or by GLP-1 receptor ago

168 The BAS-BA complex also induces glucagon-like peptide-1 (GLP-1) production by L cells wh

169 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonis

170 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), gluca

171 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist adminis

172 We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibod

173 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has be

174 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has ne

175 table therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and ba

176 New drugs for the treatment of diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists and in

177 Glucagon-like peptide-1 (GLP-1) receptor agonists and so

178 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

179 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

180 Glucagon-like peptide-1 (GLP-1) receptor agonists induce

181 Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, impro

182 olgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.

183 amine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists.

184 The glucagon-like peptide-1 (GLP-1) receptor and the glucose

185 The glucagon-like peptide-1 (GLP-1) receptors are important

186 Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors in the ventral

187 The glucagon and glucagon-like peptide-1 (GLP-1) receptors play important

188 Using optogenetic, glucagon-like peptide-1 (GLP-1) secreting cells, we cond

189 oid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrin

190 021 to be an especially potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro.

191 Glucagon-like peptide-1 (GLP-1) secretion is classically

192 Glucagon-like peptide-1 (GLP-1) seems to mediate the met

193 Glucagon-like peptide-1 (GLP-1) signaling through the gl

194 Alhough the glucagon-like peptide-1 (GLP-1) system is critical to en

195 an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects o

196 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were measured.

197 ecystokinin (CCK); peptide YY3-36 (PYY3-36); glucagon-like peptide-1 (GLP-1)) excite vagal afferent n

198 , we use the validated diabetes therapeutic, glucagon-like peptide-1 (GLP-1), and the target of clini

199 hormones, such as cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), are released following

200 -dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) a

201 We measured tastant-dependent secretion of glucagon-like peptide-1 (GLP-1), glucagon, and neuropept

202 lucose, plasma insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucose-dependent insul

203 bolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insul

204 Glucagon-like peptide-1 (GLP-1), glucose-dependent insul

205 lowering effects of a gut-released hormone, glucagon-like peptide-1 (GLP-1), has been reported in th

206 tropyloroduodenal motility, cholecystokinin, glucagon-like peptide-1 (GLP-1), insulin, glucagon, bloo

207 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), is unknown.

208 Protein increased dose-dependently glucagon-like peptide-1 (GLP-1), peptide YY (PYY) 3-36,

209 lation of an important pharmaceutical, human glucagon-like peptide-1 (GLP-1).

210 ne (gcg), which encodes the incretin hormone glucagon-like peptide-1 (GLP-1).

211 ch in turn is critical for the production of glucagon-like peptide-1 (GLP-1).

212 Glucagon-like-peptide 1 (GLP-1) is expressed not only in

213 haracterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years

214 rs prevent degradation of incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent in

215 Consistent with this model, a glucagon-like peptide 1 (GLP1) agonist, which stimulates

216 We describe this method using dulaglutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

217 Currently, only glucagon-like peptide-1 (GLP1) analogs are able to achie

218 oss-reactivity with related peptides such as glucagon-like peptide-1, glucagon-like peptide-2, gastri

219 , we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NA

220 Dual-acting glucagon-like peptide-1/glucagon receptor agonists such

221 se-dependent insulinotropic polypeptide, and glucagon-like peptide 1), glucose, and multiple AAs, inc

222 nsional ultrasound), plasma cholecystokinin, glucagon-like peptide 1, glucose-dependent insulinotropi

223 ood glucose ranged from 7.2% to 30.4% in the glucagon-like peptide-1 group and from 19.8% to 56.8% in

224 Blood glucose levels in the glucagon-like peptide-1 group were better controlled wit

225 mmol/L) in both groups were low (one in the glucagon-like peptide-1 group, three in the saline group

226 n of a long-acting analog of the gut-hormone glucagon-like peptide-1 highlights the therapeutic poten

227 ced and density of endocrine cells secreting glucagon-like peptide-1 increased.

228 h plasma concentrations of acylated ghrelin, glucagon-like peptide 1, insulin, glucose, and nonesteri

229 Glucagon-like peptide-1 is an incretin hormone capable o

230 entrations of total ghrelin, peptide YY, and glucagon-like peptide-1, leptin, adiponectin, expired 13

231 ulted in elevated C-peptide levels, elevated glucagon like peptide-1 levels and a reduction in dipept

232 in human beta-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the

233 eceptor activation, whereas responses to the glucagon-like peptide-1 or the glucagon-like peptide-1 r

234 rs in hippocampal neurons to reduce (leptin, glucagon-like peptide-1) or increase (ghrelin) food inta

235 eptide ligands, including endogenous ligands glucagon-like peptide-1, oxyntomodulin, and the clinical

236 P = .003), and higher postprandial levels of glucagon-like peptide 1 (P < .001).

237 igher early postprandial cholecystokinin and glucagon-like peptide 1 peaks than did the other partici

238 l motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon,

239 We constructed synthetic genes for glucagon-like peptide-1 PODs and demonstrated their high

240 Remarkably, a single injection of glucagon-like peptide-1 PODs was able to reduce blood gl

241 ted depletion, which could not be rescued by glucagon-like peptide 1 pretreatment.

242 The incretin hormone, glucagon-like peptide-1, promotes myocardial glucose upt

243 abetic C57BL/6J mice treated with either the glucagon-like peptide 1 receptor (GLP-1R) agonist liragl

244 Glucagon-like peptide 1 receptor (GLP-1R) agonists are i

245 like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regul

246 Glucagon-like peptide 1 receptor (GLP-1R) signaling in t

247 und that exendin-4 (Ex-4), an agonist of the glucagon-like peptide 1 receptor (GLP-1R), stimulates hu

248 ron oxide-based nanoparticle probe targeting glucagon-like peptide 1 receptor (GLP-1R), which is high

249 Glucagon-like peptide 1 receptor (GLP1R) agonists are wi

250 The short-acting glucagon-like peptide 1 receptor agonist exenatide reduc

251 ctivities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist, in Zucker diab

252 cagon was elevated, and cells expressing the glucagon-like peptide 1 receptor were more abundant in R

253 Glucagon-like peptide-1 receptor (GLP-1R) activation in

254 Central glucagon-like peptide-1 receptor (GLP-1R) activation red

255 ffects of LiCl appear to be mediated through glucagon-like peptide-1 receptor (GLP-1R) activation, we

256 Here we hypothesize that manipulating glucagon-like peptide-1 receptor (GLP-1R) activity selec

257 Exendin-4 (Ex4), a glucagon-like peptide-1 receptor (GLP-1R) agonist approv

258 ble incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liragl

259 Glucagon-like peptide-1 receptor (GLP-1R) agonists and d

260 As the anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are p

261 Glucagon-like peptide-1 receptor (GLP-1R) agonists reduc

262 The glucagon-like peptide-1 receptor (GLP-1R) and the glucag

263 Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances gluco

264 We have shown previously that the incretin glucagon-like peptide-1 receptor (GLP-1R) internalizes f

265 The glucagon-like peptide-1 receptor (GLP-1R) is a key thera

266 The glucagon-like peptide-1 receptor (GLP-1R) is a major the

267 The glucagon-like peptide-1 receptor (GLP-1R) is expressed i

268 first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive

269 tivated positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPC

270 f intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)-protein kinase

271 hibits food-motivated behaviors through vCA1 glucagon-like peptide-1 receptor (GLP-1R).

272 mpare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide wit

273 ponses to the glucagon-like peptide-1 or the glucagon-like peptide-1 receptor agonist exendin-4 were

274 smotic pump to give continuous delivery of a glucagon-like peptide-1 receptor agonist for 6-12 months

275 To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide add

276 Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of

277 ons in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glu

278 Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are

279 Both glucagon-like peptide-1 receptor agonists and dipeptidyl

280 Glucagon-like peptide-1 receptor agonists exenatide and

281 More recently, the glucagon-like peptide-1 receptor agonists liraglutide an

282 Glucagon-like peptide-1 receptor agonists may have addit

283 f dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in t

284 We assessed two glucagon-like peptide-1 receptor agonists, once-weekly a

285 CT in combination with CT (SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and c

286 The glucagon-like peptide-1 receptor is a major target for t

287 in vivo We further demonstrate that an ileal glucagon-like peptide-1 receptor-dependent neuronal netw

288 with exceptional selectivity over the human glucagon-like peptide-1 receptor.

289 tidyl-peptidase 4-inhibitor sitagliptin, the glucagon-like peptide 1-receptor agonist lixisenatide ba

290 We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascu

291 Glucagon-like peptide 1 receptors (GLP-1Rs) have been fo

292 In nonfasted rats, central antagonism of glucagon-like peptide 1 receptors partially mimics the e

293 Given that PVT neurons express glucagon-like peptide-1 receptors (GLP-1R), which are cr

294 for small non-peptide molecules to activate glucagon-like peptide-1 receptors.

295 urgery, beta-cell function, weight loss, and glucagon-like peptide 1 response were all predictors of

296 e/isoleucine, methionine, phenylalanine, and glucagon-like peptide 1 response were associated with ch

297 ly reported for LCFAs, including stimulating glucagon-like peptide-1 secretion from enteroendocrine c

298 onses to acute stress by "silencing" central glucagon-like peptide 1 signaling pathways.

299 that the addition of continuous infusion of glucagon-like peptide-1 to intensive insulin therapy wou

300 rease in alpha-cells containing glucagon and glucagon-like peptide 1 with HFS diets.